Richter C M
Department of Nephrology, Charité, Humboldt University, Berlin, Germany.
Rheumatology (Oxford). 2006 Oct;45 Suppl 3:iii36-8. doi: 10.1093/rheumatology/kel278.
Endothelin (ET)-1 is a potent vasoconstrictor with profibrotic and proinflammatory effects. Increasing evidence suggests that ET-1 and its cognate receptors are involved in a variety of progressive renal disorders, including diabetes, hypertension and glomerulonephritis. Several laboratory studies have demonstrated elevated expression of ET-1, which colocalizes with glomerular and tubulointerstitial injury, in addition to enhanced urinary excretion. Moreover, ET-1 expression correlates with disease severity and renal function. With the availability of ET receptor antagonists, a pathogenetic role has been further corroborated in animal models, demonstrating both structural and functional improvement. Thus, antagonizing the ET system may be useful in major renal pathologies associated with glomerular and tubulointerstitial damage.
内皮素(ET)-1是一种具有促纤维化和促炎作用的强效血管收缩剂。越来越多的证据表明,ET-1及其同源受体参与了多种进行性肾脏疾病,包括糖尿病、高血压和肾小球肾炎。多项实验室研究表明,ET-1表达升高,除了尿排泄增加外,它还与肾小球和肾小管间质损伤共定位。此外,ET-1表达与疾病严重程度和肾功能相关。随着ET受体拮抗剂的出现,其致病作用在动物模型中得到了进一步证实,显示出结构和功能上的改善。因此,拮抗ET系统可能对与肾小球和肾小管间质损伤相关的主要肾脏疾病有用。